Perjeta market projected to double by 2030 as HER2 breast cancer cases rise

The Perjeta (pertuzumab) market is forecast to grow from $1.08 million in 2025 to $2.23 million by 2030, driven by rising breast cancer diagnoses, broader HER2 testing and greater use of combination regimens. North America led in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - Perjeta is tied directly to HER2-positive breast cancer treatment, so market growth tracks the spread of targeted oncology care. - Rising diagnosis rates and better HER2 detection are expanding the pool of patients eligible for pertuzumab-based therapy. - The market’s projected growth signals deeper adoption of precision oncology and combination treatment approaches.

What happened: - The Business Research Company projected the global Perjeta (pertuzumab) market will rise from $1.08 million in 2025 to $1.26 million in 2026. - The report forecasts the market will reach $2.23 million by 2030. - The report said the market is growing at a 15.7% CAGR in the 2025-2026 period and at a 15.4% CAGR through 2030. - North America held the largest regional share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company also said its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, and updated graphics and tables. - More information is available in the full report.

The details: - Perjeta, also known as pertuzumab, is a monoclonal antibody used for certain breast cancers that express HER2. - The drug binds to the HER2 protein, which helps drive cancer cell growth in HER2-positive breast cancer. - Perjeta is commonly used with trastuzumab and chemotherapy. - The report linked historical growth to HER2 monoclonal antibody approvals, rising breast cancer cases, improved HER2 diagnostics, positive clinical trial results and inclusion in oncology treatment guidelines. - Forecast growth is tied to better identification of HER2-positive patients, greater use in adjuvant therapy, more combination regimens, higher oncology drug spending and broader global penetration. - The report said key trends include wider use of HER2-targeted combination therapies, expansion in early-stage and metastatic breast cancer, broader dual HER2 blockade strategies, more precision oncology and improved survival for HER2-positive tumors. - The report cited UK-based charity Ray of Light Wales, which said about 600,000 people in the UK were living with a breast cancer diagnosis in October 2023 and projected that figure could reach 1.2 million by 2030. - The report also said the rise in breast cancer cases is linked to higher obesity rates, sedentary behavior and expanded screening.

Between the lines: - The report suggests pertuzumab’s market is not just growing from one drug’s use, but from a wider shift toward biomarker-driven cancer treatment. - North America’s lead points to mature adoption and reimbursement systems, while Asia-Pacific’s expected pace suggests room for faster expansion as diagnostics and oncology access improve. - The company’s added analytics tools indicate the report is aimed at investors and industry planners looking for market sizing and regional opportunity mapping.

What's next: - Perjeta demand is likely to rise as more HER2-positive patients are identified earlier and treated with combination regimens. - The fastest growth may come from markets where HER2 testing and oncology drug access continue to broaden. - The report points to continued expansion through 2030, with adjuvant and metastatic use both contributing to demand. - More information is available in the sample request.